Integrated Proteins Limited held its Extraordinary General Meeting (EGM) on August 20, 2026, securing shareholder approval for significant corporate governance changes and capital structure adjustments. The meeting, conducted through Video Conferencing and Other Audio-Visual Means (VC/OAVM), focused on a proposed share split and key director appointments.

Key Resolutions Approved

The primary agenda item was the sub-division of the company’s equity shares. Shareholders approved splitting each existing equity share with a face value of ₹10 into 10 equity shares with a face value of ₹1 each. This action requires a corresponding alteration to the Capital Clause of the Memorandum of Association to reflect the new share structure.

Board Composition Changes

The EGM also addressed board composition. Members regularized Mr. Nitesh Pratapray Mehta (DIN: 09555034) as a Non-Executive Director. Furthermore, a special resolution was passed to reappoint Mr. Hiren Shah (DIN: 09842161) as Chairman and Managing Director. His new term spans five years, commencing on July 24, 2026, and concluding on July 23, 2031.

Meeting Conduct and Voting

The meeting commenced at 1:00 pm and concluded at 1:22 pm. Ms. Ankita Shah, a Practicing Company Secretary, served as the scrutinizer for the e-voting process. Remote e-voting was conducted in accordance with Section 108 of the Companies Act, 2013, and Regulation 44 of the SEBI LODR Regulations, 2015. Members who had not voted remotely were permitted to use the Insta-Poll facility during the live session.

The company will communicate the final voting results to BSE Limited within two working days, by August 22, 2026, and publish them on its official website. The proceedings were compliant with Regulation 30 of the SEBI LODR Regulations, 2015.

Integrated Proteins Limited reported a standalone net profit of ₹36.26 lakh for the quarter ended June 30, 2026, marking a substantial recovery from the near-zero profit of ₹0.01 lakh recorded in the same period last year. Revenue from operations expanded by 8.8% year-on-year to ₹1,056.38 lakh, up from ₹971.07 lakh in Q1FY25.

The company’s profitability improved sharply as pre-tax profits rose to ₹48.45 lakh from ₹0.01 lakh in the prior year. This operational turnaround was supported by higher top-line growth, with revenue also increasing 88.5% quarter-on-quarter compared to ₹560.53 lakh in Q4FY25.

Financial Performance

The Board of Directors approved the unaudited standalone financial results at a meeting held on August 14, 2026. The figures were reviewed by the Audit Committee and prepared in accordance with Indian Accounting Standard (Ind AS) 34.

Earnings per share (basic and diluted) stood at ₹0.19 for the quarter, compared to ₹0.00 in the corresponding period of the previous fiscal year. For the full year ended March 31, 2026, the company reported a net profit of ₹22.50 lakh on revenue of ₹994.07 lakh.

What the Numbers Show

The divergence between revenue growth and profit expansion highlights a significant improvement in cost efficiency or margin structure. While revenue grew moderately by 8.8% year-on-year, pre-tax profits surged over 48,000 times, suggesting that fixed costs were better absorbed or variable costs declined significantly relative to sales volume. This indicates a potential inflection point in operational leverage for the protein processing business.